Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Topical mitomycin-C for pterygia: is single application appropriate?

R S Rubinfeld1, R M Stein

  • 1Department of Ophthalmology/Center for Sight, Georgetown University Medical Center, Washington, DC, USA.

Ophthalmic Surgery and Lasers
|August 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methicillin-resistant Staphylococcus aureus ulcerative keratitis after laser in situ keratomileusis.

Journal of cataract and refractive surgery·2001
Same author

Case reports and small case series: LASIK-associated visual field loss in a glaucoma suspect.

Archives of ophthalmology (Chicago, Ill. : 1960)·2001
Same author

Ocular deposition of copper associated with multiple myeloma.

American journal of ophthalmology·2001
Same author

Latino physician supply in California: sources, locations, and projections.

Academic medicine : journal of the Association of American Medical Colleges·2000
Same author

Communicating with laser vision correction patients.

Journal of ophthalmic nursing & technology·2000
Same author

Corneal cooling and rehydration during photorefractive keratectomy to reduce postoperative corneal haze.

Journal of refractive surgery (Thorofare, N.J. : 1995)·1999

Mitomycin-C significantly reduces pterygium recurrence, especially with intraoperative application combined with conjunctival closure. Lower dosages and shorter durations increase recurrence rates, highlighting the need for careful dosing strategies.

Area of Science:

  • Ophthalmology
  • Surgical Oncology
  • Pharmacology

Background:

  • Mitomycin-C (MMC) is effective in reducing pterygium recurrence.
  • High cumulative doses of MMC are linked to serious complications.
  • Investigating reduced MMC dosages is crucial for safety and efficacy.

Purpose of the Study:

  • To evaluate the safety and efficacy of varying Mitomycin-C dosages for pterygium surgery.
  • To determine optimal MMC dosing to minimize recurrence and complications.

Main Methods:

  • Prospective nonrandomized trial involving 481 pterygium excisions.
  • Utilized five distinct Mitomycin-C dosages and treatment durations.
  • Defined recurrence as fibrovascular tissue regrowth onto the cornea.

Related Experiment Videos

Main Results:

  • Control group (no MMC) had a 65% recurrence rate.
  • 0.4 mg/ml MMC for 2 weeks yielded 2.5% recurrence but 10% complications.
  • Intraoperative 0.2 mg/ml MMC with conjunctival closure showed 2.7% recurrence and no complications.

Conclusions:

  • Intraoperative Mitomycin-C with conjunctival closure is highly effective in preventing pterygium recurrence.
  • Lower dosages or shorter durations may increase recurrence rates.
  • Surgeons must exercise caution due to MMC's potency and the need for further randomized trials.